22:40:02 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-11-09 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-22 Ordinarie utdelning STENO 0.00 DKK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-18 Extra Bolagsstämma 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning STENO 0.00 DKK
2022-05-19 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning STENO 0.00 DKK
2021-05-20 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning STENO 0.00 DKK
2020-05-14 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-06 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-07 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018


ListaFirst North Denmark
IndustriLäkemedel & Handel
Stenocare är verksamma inom hälsovårdsindustrin. Bolaget är specialiserade inom utveckling av medicinsk cannabis. Stenocare är en av de första aktören att ha påbörjat försäljning av medicinska cannabisoljor i Danmark. Bolaget kommer framöver även vända sig till övriga europeiska marknader med sitt produktutbud. Stenocares huvudkontor ligger i Randers.
2023-03-16 15:40:49


The Board of Directors and the Chief Executive Officer of STENOCARE A/S ("STENOCARE") hereby publishes the annual report of the fiscal year 2022. The annual report including the auditor's report is available as an attached file and on the website of STENOCARE (https://stenocare.com/investor-relations/) and Nasdaq First North (http://www.nasdaqomxnordic.com/shares/microsite?Instrument=CSE196164).

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

"We are now a European leader within prescription-based medical cannabis and by the end of 2023 we expect to reach a quarterly break-even along with continued growth in the number of markets, products and doctors that prescribe medical cannabis for treatment of chronic pain and more.

In 2022, our four strategic assets paid off:
  • Regulatory: We continued to be the only company in Denmark to have medical cannabis oil products accepted into the Danish Pilot program and make them available for patients. 
  • Supply chain: We now have a strong product portfolio for patients. We continued to strengthen our supply relation with our key supplier and others.  Also, our own factory is coming closer to commercial launch of own products.
  • Commercial: From the outset of 2022, we were selling 2 products in 1 country. At the end of the year, we were selling 11 products in 5 countries. We ended the year with a record quarterly sale of 2.8 mDKK that adds up to 4.5 mDKK for the full year - which is a growth of 181% versus 2021.
  • Partnerships: With our development partner, we entered into a new phase with the completion of a pharmacokinetic study. We received data that makes us optimistic regarding developing the next generation of medical cannabis oil products.

With 5 markets in place out of our target of 10 by 2025, advanced pharma grade products on the horizon and break-even in sight for end 2023. I can proudly say that we are stronger than ever".